Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0B5EB
|
||||
Former ID |
DIB011699
|
||||
Drug Name |
Ponezumab
|
||||
Synonyms |
Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219
|
||||
Drug Type |
Antibody
|
||||
Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 2 | [524248] | ||
Company |
Rinat Neuroscience Corp
|
||||
CAS Number |
CAS 1178862-65-1
|
||||
Target and Pathway | |||||
Target(s) | Amyloid beta A4 protein | Target Info | [531746] | ||
KEGG Pathway | Notch signaling pathway | ||||
Alzheimer's disease | |||||
Reactome | Nuclear signaling by ERBB4 | ||||
Degradation of the extracellular matrix | |||||
Regulated proteolysis of p75NTR | |||||
NRIF signals cell death from the nucleus | |||||
Activated NOTCH1 Transmits Signal to the Nucleus | |||||
Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
EPH-ephrin mediated repulsion of cells | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.